 MONT-SAINT-GUIBERT, Belgium--BUSINESS WIRE--Regulatory News: Celyad Oncology SA Brussels:CYAD Paris:CYAD NASDAQ:CYAD Euronext Nasdaq: CYAD, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell CAR T therapies for cancer, today announced that the Company will report full year 2020 financial and operating results on the evening of Wednesday, March 24th. Following the press release, Celyad management will host a confe 